An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

The success of infliximab paved the way for the introduction of other drugs with a similar mechanism of action. Three other TNF-blocking agents (etanercept, adalimumab and certolizumab pegol) are ...

“Anti-MCV antibodies might, therefore, be useful in monitoring response to infliximab therapy...” After adjustment of the anti-MCV assay to produce the same specificity as the anti-CCP assay ...

Infliximab works by blocking a molecule called tumor necrosis factor (TNF), which is a major part of the body’s immune ...

The REMSIMA® biosimilar of Infliximab from J&J has recently been awarded in the Umbria bids and is expected to be supplied for two years until 2027. The subcutaneous injection (SC) product of ...